$7 Mil for NeuroSearch Psych Prog
It was announced today that NeuroSearch, a Danish biotech research firm focused on psychiatric disease, has received a payment of approximately $7 million as part of their strategic alliance that was initiated in December 2003.
The partnership is focused on the drug candidate NS2359 (GSK372475), which is in clinical phase II development for the treatment of depression. In addition, the alliance comprises a number of research programs within ion channels and the treatment of diseases of the central nervous system (CNS), including anxiety and schizophrenia.
Source: Pharmalive
Posted by szadmin at February 25, 2005 06:07 PM
More Information on
Schizophrenia Medications
